Fintel reports that on August 16, 2023, Roth MKM maintained coverage of Delcath Systems (NASDAQ:DCTH) with a Buy recommendation.
Analyst Price Forecast Suggests 195.03% Upside
As of August 2, 2023, the average one-year price target for Delcath Systems is 16.73. The forecasts range from a low of 10.10 to a high of $23.10. The average price target represents an increase of 195.03% from its latest reported closing price of 5.67.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Delcath Systems is 12MM, an increase of 368.83%. The projected annual non-GAAP EPS is -2.13.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Delcath Systems. This is an increase of 7 owner(s) or 17.95% in the last quarter. Average portfolio weight of all funds dedicated to DCTH is 0.05%, an increase of 63.03%. Total shares owned by institutions increased in the last three months by 156.93% to 3,412K shares. 
The put/call ratio of DCTH is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 1,179K shares representing 7.72% ownership of the company.
Logos Global Management holds 1,179K shares representing 7.72% ownership of the company.
Stonepine Capital Management holds 379K shares representing 2.48% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 255K shares representing 1.67% ownership of the company. No change in the last quarter.
Kent Lake Capital holds 219K shares representing 1.44% ownership of the company. No change in the last quarter.
Delcath Systems Background Information
(This description is provided by the company.)
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Additional reading:
- Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT
- Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to ce
- Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
